Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response

Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an antiviral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses and the development of monoclonal antibody (mAb) resistance is a critical area of inv...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marc-Kendy Paul, Manish Choudhary, Amy Heaps, Rinki Deo, Daniela Moisi, Kelley Gordon, John Mellors, Carlee Moser, Paul Klekotka, Alan Landay, Judith Currier, Joseph Eron, Kara Chew, Davey Smith, Scott Sieg, Urvi Parikh, Jonathan Li
Format:	Artigo
Idioma:	Inglês
Publicat:	Case Western Reserve University 2024-08-01
Col·lecció:	Pathogens and Immunity
Matèries:	bamlanivimab COVID-19 monoclonal antibody SARS-CoV-2 pseudovirus neutralization
Accés en línia:	https://www.paijournal.com/index.php/paijournal/article/view/718
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!